Glucagon-like peptide-1 analog: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}})) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
| Line 18: | Line 18: | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
{{Oral hypoglycemics and insulin analogs}} | {{Oral hypoglycemics and insulin analogs}} | ||
[[Category:Hormones]] | [[Category:Hormones]] | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Latest revision as of 17:52, 4 September 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Glucagon-like peptide-1 analogs are a new class of drug for treatment of type 2 diabetes. [1] One of their advantages is that they have a lower risk of causing hypoglycemia.
Licenced:
- exenatide (2005)
Under investigation:
- albiglutide
- taspoglutide
References
- ↑ http://www.medscape.com/viewarticle/578304 "Glucagon-like Peptide-1 Analogs Other Than Exenatide"